Browse FOLR1

Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Lipid-anchor, GPI-anchor. Secreted Cytoplasmic vesicle. Cytoplasmic vesicle, clathrin-coated vesicle. Endosome. Apical cell membrane Note=Endocytosed into cytoplasmic vesicles and then recycled to the cell membrane.
Domain PF03024 Folate receptor family
Function

Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001667 ameboidal-type cell migration
GO:0001755 neural crest cell migration
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0001947 heart looping
GO:0003007 heart morphogenesis
GO:0003143 embryonic heart tube morphogenesis
GO:0003147 neural crest cell migration involved in heart formation
GO:0003151 outflow tract morphogenesis
GO:0003253 cardiac neural crest cell migration involved in outflow tract morphogenesis
GO:0006575 cellular modified amino acid metabolic process
GO:0006732 coenzyme metabolic process
GO:0006760 folic acid-containing compound metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006898 receptor-mediated endocytosis
GO:0006900 membrane budding
GO:0006901 vesicle coating
GO:0006903 vesicle targeting
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007368 determination of left/right symmetry
GO:0007389 pattern specification process
GO:0007507 heart development
GO:0007584 response to nutrient
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0009991 response to extracellular stimulus
GO:0014020 primary neural tube formation
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0015849 organic acid transport
GO:0015884 folic acid transport
GO:0016050 vesicle organization
GO:0016055 Wnt signaling pathway
GO:0016331 morphogenesis of embryonic epithelium
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0021915 neural tube development
GO:0030111 regulation of Wnt signaling pathway
GO:0031099 regeneration
GO:0031102 neuron projection regeneration
GO:0031103 axon regeneration
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031670 cellular response to nutrient
GO:0033273 response to vitamin
GO:0035050 embryonic heart tube development
GO:0035051 cardiocyte differentiation
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0042558 pteridine-containing compound metabolic process
GO:0042886 amide transport
GO:0046655 folic acid metabolic process
GO:0048193 Golgi vesicle transport
GO:0048199 vesicle targeting, to, from or within Golgi
GO:0048207 vesicle targeting, rough ER to cis-Golgi
GO:0048208 COPII vesicle coating
GO:0048514 blood vessel morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048645 animal organ formation
GO:0048678 response to axon injury
GO:0048762 mesenchymal cell differentiation
GO:0048844 artery morphogenesis
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0051180 vitamin transport
GO:0051181 cofactor transport
GO:0051186 cofactor metabolic process
GO:0051593 response to folic acid
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0060037 pharyngeal system development
GO:0060070 canonical Wnt signaling pathway
GO:0060485 mesenchyme development
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0060840 artery development
GO:0060914 heart formation
GO:0060973 cell migration involved in heart development
GO:0060974 cell migration involved in heart formation
GO:0061307 cardiac neural crest cell differentiation involved in heart development
GO:0061308 cardiac neural crest cell development involved in heart development
GO:0061309 cardiac neural crest cell development involved in outflow tract morphogenesis
GO:0061371 determination of heart left/right asymmetry
GO:0061564 axon development
GO:0061626 pharyngeal arch artery morphogenesis
GO:0061713 anterior neural tube closure
GO:0071229 cellular response to acid chemical
GO:0071231 cellular response to folic acid
GO:0071295 cellular response to vitamin
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071496 cellular response to external stimulus
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0072175 epithelial tube formation
GO:0072337 modified amino acid transport
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090114 COPII-coated vesicle budding
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0198738 cell-cell signaling by wnt
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
Molecular Function GO:0005542 folic acid binding
GO:0008144 drug binding
GO:0008517 folic acid transporter activity
GO:0019842 vitamin binding
GO:0031406 carboxylic acid binding
GO:0033218 amide binding
GO:0038024 cargo receptor activity
GO:0043168 anion binding
GO:0043177 organic acid binding
GO:0051183 vitamin transporter activity
GO:0051184 cofactor transporter activity
GO:0051870 methotrexate binding
GO:0061714 folic acid receptor activity
GO:0072341 modified amino acid binding
Cellular Component GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0005903 brush border
GO:0009897 external side of plasma membrane
GO:0012507 ER to Golgi transport vesicle membrane
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0031225 anchored component of membrane
GO:0031233 intrinsic component of external side of plasma membrane
GO:0031253 cell projection membrane
GO:0031362 anchored component of external side of plasma membrane
GO:0031526 brush border membrane
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0045177 apical part of cell
GO:0046658 anchored component of plasma membrane
GO:0098552 side of membrane
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-5694530: Cargo concentration in the ER
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FOLR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FOLR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27445334Ovarian CarcinomaEssential for immunotherapyAs a proof of concept, we chemically programmed h38C2 × v9 with hapten-folate and demonstrated its selectivity and potency against folate receptor 1 (FOLR1)-expressing ovarian cancer cells in vitro and in vivo Unlike conventional biAbs, chemically programmed biAbs in DART format are highly modular with broad utility in terms of both target and effector cell engagement. Most importantly, they provide tumor-targeting compounds access to the power of cancer immunotherapy.
29628923melanomaPromote immunityTo establish this, we selected Folate Receptor alpha (FRα) as a model antigen and a mouse B cell line, expressing both the soluble and the membrane-bound forms of a human/mouse chimeric antibody (MOv18 IgG1) specific for FRα, as test antibody-expressing cells.
16908932Breast carcinoma; Ovarian carcinomaPromote immunityThese findings demonstrate that the FRalpha is a target of the immune system in breast and ovarian cancer patients. Understanding which antigens are targeted by the immune system may be important for prognosis or immune-based therapies.
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FOLR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FOLR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.550.231
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.440.0603
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0840.892
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5730.422
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0060.424
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0220.989
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.3320.0998
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5640.717
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.2030.19
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.090.607
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5260.869
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0220.957
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FOLR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOLR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOLR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOLR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOLR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FOLR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FOLR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFOLR1
Namefolate receptor 1 (adult)
Aliases FOLR; FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor, adult; ......
Chromosomal Location11q13.3-q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FOLR1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FOLR1.
ID Name Drug Type Targets #Targets
DB00158Folic AcidSmall MoleculeFOLR1, FOLR2, FOLR33
DB05168VintafolideSmall MoleculeFOLR1, FOLR2, FOLR33
DB05595FarletuzumabBiotechFOLR11